Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

March 28, 2025

Study Completion Date

April 28, 2025

Conditions
Insulin Resistance Syndrome
Interventions
DEVICE

Hyperbaric oxygen therapy

Hyperbaric Oxygen Therapy (HBOT):(Haux, Starmed 2300, Germany). A multichamper Double-lock, divided into Main chamber and Antichamber, with omega Ω-shape and all safety and CE-Certificate,

DRUG

Hypoglycemic Drug

"Metformin reduces serum glucose level by several different mechanisms without increasing insulin secretion.it increases the effects of insulin so it is termed insulin sensitizer ,metformin also suppresses the endogenous glucose production by the liver ,which is mainly due to a reduction in the rate of gluconeogenesis and asmall effect on glycogenolysis. Moreover, metformin activates the enzyme adenosine monophosphate kinase (AMPK) resulting in the inhibition of key enzymes involved in gluconeogenesis and glycogen synthesis in the liver while stimulating insulin signaling and glucose transport in muscles"

Trial Locations (1)

3753450

RECRUITING

Kobry el koba military complex, Cairo

All Listed Sponsors
lead

Cairo University

OTHER